Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P00750 (PLA)
 16,800 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Neuropeptide Y (NPY) has been recently characterised as one of the strongest circulating vasoconstrictor peptides, its elevated level may cause coronary artery spasm and increase of peripheral vascular resistance. All this contributes to ischemic myocardial damage and decrease of regional and global left ventricular function. The aim of the study was the examination of NPY plasma levels in patients with acute myocardial infarction (AMI) after thrombolytic therapy with or without reperfusion. The survey was made in 82 patients with AMI after thrombolytic therapy: 40 of them without reperfusion and 42 with reperfusion. The control group consisted of 20 healthy persons. Plasma levels of NPY were measured before thrombolysis, then 1, 3 and 5 days after, using a radioimmunologic method. All patients were treated with aspirin, glyceryl trinitrate and thrombolytic therapy (TT) with alteplase (r-TPA). In patients with AMI, NPY plasma levels were normal before and 1 day after TT, and were significant elevated 3 days after TT 5 days after TT, plasma NPY levels were still high in patients without reperfusion, but they decreased in patients with reperfusion. There was significant negative correlation between NPY level and left ventricular ejection fraction measured 5 days after AMI. During 30-days follow up systolic dysfunction of left ventricle with ejection fraction under 40% occurred in 21 patients and in 11 of them clinical symptoms of heart failure were observed. Using the multivariable regression analysis we showed that NPY concentration over 60 pg/ml is the independent factor leading to left ventricle systolic dysfunction. The results of our study suggest the contribution of NPY to the left ventricular remodeling after AMI.
Pol Arch Med Wewn 2001 Feb
PMID:[Plasma levels of neuropeptide Y i patients with current myocardial infarction]. 1150 45

The study was carried out in a group of 285 children and adolescents aged 4-20 yrs. Children were divided according to their main disease: group with obesity, obesity and coexisting hypertension, hypertension and diabetes. Each group was divided into children with positive or negative family history of cardiovascular diseases. We assessed routine lipid parameters, body mass index and new atherosclerosis risk factors: lipoprotein (a), apolipoproteins A-I and B, homocysteine, fibrinogen, t-PA and PAI-1. Positive family history of cardiovascular diseases was found in 28% families, and in 8% families it was premature cardiovascular disease. In 48% children we found hypertension in family. Children with positive family history had significantly higher body mass index (25.4 vs 23.8 kg/m2). In the group with obesity and hypertension we found significantly higher cholesterol (182 vs 160 mg/dl) and LDL-cholesterol level (114 vs 93 mg/dl). Lipoprotein(a) level was significantly higher in children with positive family history (38 vs 28 mg/dl). Significant differencies were also found in apolipoprotein B level (90 vs 84 mg/dl). In logistic regression analysis only BMI and lipoprotein(a) were significant in predicting future cardiovascular events in children. Obese, hypertensive and diabetic children often come from families with cardiovascular diseases. Hypertension is the most often prevalent atherosclerosis risk factor in families. Children with positive family history of cardiovascular diseases have significantly higher body mass index. Out of new atherosclerosis risk factors lipoprotein(a) and apolipoprotein B may have real value in predicting future cardiovascular disease in the child. The aim of the study was to compare obese, hypertensive and diabetic children with positive and negative family history of cardiovascular diseases. In the work we have tried to find which of the new atherosclerosis risk factors may have the real value in predicting future cardiovascular events in children already predisposed to atherosclerosis.
Pol Merkur Lekarski 2002 Feb
PMID:[Correlation between body mass index, lipoprotein (a) level and positive family history of cardiovascular diseases in children and adolescents with obesity, hypertension and diabetes]. 1199 45

Classical thrombolytic treatment in acute myocardial infarction is able to reach reperfusion in 60-80% of patients, however in 5-10% of cases reoclusion occurs. Primary percutaneous coronary intervention (PCI) offers the potential for a higher rate of reperfusion and a lower rate of bleeding events. Recently, advances in platelet inhibition and PCI procedures have led to the combination of all the approaches. Facilitated PCI or the use of elective PCI after pharmacological reperfusion therapy can combine the best aspects of thrombolysis and mechanical revascularization in acute myocardial infarction. However, in some cases PCI cannot be performed. This paper describes a patient with acute myocardial infarction successfully treated with intracoronary infusion of alteplase and GP IIb/IIIa inhibitor.
Kardiol Pol 2003 Jan
PMID:[Intracoronary administration of the combined fibrinolytic therapy a in patient with acute myocardial infarction and end-stage coronary heart disease - a case report]. 1450 3

This study demonstrates the usefulness of PLA and nested-PCR methods for the detection of cattle infection with enzootic bovine leukemia virus. Serological control with PLA was by 1.7% more sensitive than reference ELISA examination. Both the DNA of env-BLV gene in NCR, V-NCR, FLK and in recombinated AG clone cells, as well as in the whole blood and in blood isolated leukocytes of dairy cattle, were detected with the nested-PCR.
Pol J Vet Sci 2003
PMID:The improvement of monitoring methods of cattle infection with bovine leukemia virus (BLV). 1450 60

The aim of the present study was to evaluate fibrinolysis in patients with lichen planus. In blood of 20 patients (12 women, 8 men) the levels of tissue type plasminogen activator (t-PA), plasmin-antiplasmin complexes (PAP) and D-dimer were examined. The control group consisted of 37 healthy volunteers. The concentrations of t-PA, PAP and D-dimer were higher in patients with lichen planus in comparison with the control group. It seems that increased level of t-PA antigen in the blood of the patients with lichen planus was the effect of t-PA releasing from endothelial cells. The results of the present study suggest that increased concentrations of t-PA antigen, PAP and D-dimer were the evidence of higher activity of fibrinolysis system in subjects with lichen planus.
Pol Merkur Lekarski 2003 Jul
PMID:[Plasmin-alpha 2-antiplasmin complexes in blood of patient with lichen planus against the background of other fibrinolysis parameters]. 1459 65

Laryngeal cancer is the most common neoplasm of the head and neck region. Laryngeal cancer patients experience thromboembolic complications more often than the general population. Our previous studies revealed in loco activation of blood coagulation in laryngeal cancer. The purpose of the present study was to examine the interactions among the laryngeal cancer cells and fibrinolytic system components in loco. Twenty-two cases of squamous carcinoma of the larynx were examined. AMeX method-preserved cancer tissues were examined using immunohistochemical ABC method. Fibrin and D-D fibrin dimers were demonstrated in the matrix, predominantly on the tumor-host front. Plasminogen, tissue-type plasminogen activator (t-PA) and plasmin were detected in cancer cells, but the intensity of their expression revealed a negative correlation with the degree of malignancy. A weak expression of high molecular weight urokinase (HMW-UK) was observed in cancer cells in the centers of the cancer foci, and a product of its degradation--low molecular weight urokinase (LMW-UK) was observed in cancer cells on the invasion front. The presence of plasminogen activator inhibitors (PAI-1, PAI-2, PAI-3) was also documented in the cancer cells. The expression of urokinase receptor (u-PAR) was very weak. Based on the results of the study, we suggest that in laryngeal cancer a suboptimal activation of fibrinolysis occurs that contributes to fibrin deposition in the tumour.
Pol Merkur Lekarski 2003 Jul
PMID:[The location of components of fibrinolytic system in laryngeal cancer]. 1459 67

The aim of the work was to study the influence of extracorporal circulation (ECC) on the vascular endothelial markers: von Willebrand factor (vWf), tissue plasminogen activator (t-PA) and trombomodulin (TM) in patients with coronary heart disease (CHD) undergoing coronary artery bypass graft (CABG). Examined group consisted of 30 patients (22 men, 8 women) at mean age 58.0 +/- 8.0 years, among them 19--were operated with ECC, 11--without ECC. Before and during operation blood was drawn 6 times. Control group consisted of 23. healthy volunteers at similar age. In the plasma vWf, t-PA and TM were determined with immunoenzymatic methods. Before operation the examined parameters were significantly higher compared to controls. The concentration of vWf during ECC was higher than in operation without ECC, but not significant. Differences statistically significant in the blood collected during ECC and without it appeared in t-PA only on the 3. and in TM on the 1. and 3. day after operation. It seems that ECC does not damage vascular endothelium direct, only indirect trough proinflammatory factors released from activated during ECC granulocytes and platelets.
Pol Merkur Lekarski 2003 Aug
PMID:[Does extracorporeal circulation during coronary artery bypass grafting damage vascular endothelium?]. 1464 77

Disturbances of lipids metabolism described in obese persons are important factor damaging vascular endothelium. Known markers of endothelium impairment are: von Willebrand factor (vWf), tissue plasminogen activator (t-PA:Ag) and thrombomodulin (TM). The aim of the work was to evaluate markers of the endothelial disturbance in the blood plasma of persons with obesity. The study was performed in the group of 50 obese persons (39 W, 11 M) aged 35-65 (means 48.8) years with abdominal obesity. The control group consisted of 30 healthy volunteers aged 25-56 (means 41.0) years. In the poor platelet plasma obtained from venous citric blood concentrations of TM, von Willebrand factor antigen (vWf:Ag) and tissue plasminogen activator antigen (t-PA:Ag) were determined using immunoenzyme-linked assay (ELISA). In the obese persons significantly higher concentration of vWf:Ag and t-PA:Ag in comparison to control group. Analysis of results obtained according sex showed that in the blood plasma of obese women TM concentration was significantly higher than in healthy women. Our study proved that in the blood plasma of obese men there are evidences of impairment of endothelial function as higher concentration of vWf:Ag and t-PA:Ag, but in the group of obese women as the increased TM concentration.
Pol Merkur Lekarski 2003 Dec
PMID:[Thrombomodulin, von Willebrand factor and tissue plasminogen activator in the blood plasma of obese women and men]. 1505 51

Effect of three epsilon-aminocaproylaminoacids with a significant antifibrinolytic activity on amidolytic activity of tissue plasminogen activator (t-PA), urokinase and kallikrein was examined. epsilon-Aminocaproyl-S-benzyl)-L-cysteine and epsilon-aminocaproyl-L-norleucine were weak inhibitors of kallikrein. Weak activation of t-PA activity was observed at high concentration of the tested compounds. Only one of the examined dipeptides was a weak inhibitor of amidolytic activity of urokinase.
Acta Pol Pharm
PMID:Effects of epsilon-aminocaproiloaminoacids on the amidolytic activity of tissue plasminogen activator, urokinase and kallikrein. 1525 61

Coronary artery disease is a leading cause of mortality in highly developed societies. This occurs in spite of growing therapeutic opportunities. Atherosclerosis begins as a functional or/and structural damage of endothelium, which in turn causes its discontinuation and impairs humoral and secreting function. Haemostasis plays an important role in the progression of atherosclerosis and development of cardiac complications--acute coronary syndromes. Research still continues to determine precisely role of each of haemostasis disorders in increased risk of coronary artery disease and its complications. The aim of this paper is to review the literature data concerning haemostatic risk factors and their role of development of coronary artery disease. Fibrinogen, thrombocytes, factor VII, factor VIII, von Willebrand factor (vWF), thrombomodulin (TM), plasminogen activator inhibitor--type 1 (PAI-1), tissue-plasminogen activator (t-PA) and other haemostatic factors, were described as more or less helpful in estimation of risk of occurrence of coronary artery disease and its cardiovascular complications. Only some of the described hematologic factors were verified so far in large prospective studies, and were recognized as independent risk factors of cardiovascular diseases.
Pol Merkur Lekarski 2004 May
PMID:[Role of the hemostatic system in pathogenesis of atherosclerosis as the main etiology of coronary ischemia] [corrected]. 1551 28


<< Previous 1 2 3 4 5 6 Next >>